ANIP - ANI Pharmaceuticals, Inc.
59.33 0.00 (0.00%)
After hours: 4:00PM EST
| Previous Close | 57.71 |
| Open | 57.92 |
| Bid | 59.21 x 900 |
| Ask | 59.45 x 1100 |
| Day's Range | 57.75 - 59.50 |
| 52 Week Range | 53.55 - 86.96 |
| Volume | 60,422 |
| Avg. Volume | 88,304 |
| Market Cap | 717.359M |
| Beta (5Y Monthly) | 1.91 |
| PE Ratio (TTM) | 44.38 |
| EPS (TTM) | 1.34 |
| Earnings Date | Feb 26, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 75.00 |
- GuruFocus.com
3 Fast-Growing CapEx Stocks
Growth may follow after five years of massive allocation of funds to projects and investments Continue reading...
- Simply Wall St.
Read This Before Judging ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) ROE
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- PR Newswire
ANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Year-to-Date 2019 Financial Results
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and year-to-date 2019 financial results on Thursday, February 27, 2020, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
- Zacks
Earnings Preview: ANI Pharmaceuticals (ANIP) Q4 Earnings Expected to Decline
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
ANI Announces Launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL
ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL. The current annual market for this product is approximately $29 million, according to IQVIA. This launch represents ANI's third generic product introduction in 2020.
- PR Newswire
ANI Announces Launch of Tolterodine Extended-Release Capsules
ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Tolterodine Extended-Release Capsules, 2 mg and 4 mg. The current annual U.S. market for this product is approximately $101 million, according to IQVIA.
- PR Newswire
ANI Pharmaceuticals Announces FDA Approval of Potassium Citrate Extended-Release Tablets USP
ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) for Potassium Citrate Extended-Release Tablets USP, 10 mEq and 15 mEq. The current annual U.S. market for this product is approximately $75 million, according to IQVIA.
- Simply Wall St.
Is ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Pay Justified?
In 2013 Arthur Przybyl was appointed CEO of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). This analysis aims first to...
- PR Newswire
ANI Announces Launch of Paliperidone Extended-Release Tablets
ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg. The current annual U.S. market for this product is approximately $342 million, according to IQVIA.
- PR Newswire
ANI Pharmaceuticals Announces Acquisition of Commercial and Pipeline Generic Products from Amerigen Pharmaceuticals, Ltd.
ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the acquisition of the U.S. portfolio of 23 generic products from Amerigen Pharmaceuticals, Ltd. for $52.5M in cash at close and up to $25M in contingent profit share payments over the next four years. The contingent payments are earned when annual gross profit exceeds a minimum threshold and are earned on a subset of the acquired products. The acquired portfolio includes ten commercial products, three approved products with launches pending, four filed products and four in-development products as well as a license to commercialize two approved products. The transaction was funded from cash on hand.
- Zacks
4 Drug/Biotech Outperformers That May Lose Steam in 2020
Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
- PR Newswire
ANI Pharmaceuticals Announces Launch of Bretylium Tosylate Injection, USP 50 mg/mL
ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Bretylium Tosylate Injection USP, 50 mg/mL. Bretylium Tosylate is a class III antiarrhythmic medication approved for the treatment of ventricular fibrillation and life-threatening ventricular arrhythmias such as ventricular tachycardia. ANI estimates that the current annual U.S. antiarrhythmic market is approximately $915 million, based on data from IQVIA.
- Insider Monkey
Is ANI Pharmaceuticals Inc (ANIP) Going To Burn These Hedge Funds ?
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability […]
- Simply Wall St.
Before You Buy ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), Consider Its Volatility
If you own shares in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) then it's worth thinking about how it contributes to the...
- Zacks
New Strong Sell Stocks for December 4th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- Zacks
Moving Average Crossover Alert: ANI Pharmaceuticals
ANI Pharmaceuticals could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
- PR Newswire
ANI Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will present on December 3, 2019 at the Evercore ISI HealthCONx Conference in Boston, Massachusetts. Arthur Przybyl, President and CEO, Robert Schrepfer, Senior Vice President Business Development & Specialty Sales, and Mark Ginski, Vice President Cortrophin Product Development, will present at 10:15 AM ET on Tuesday, December 3, 2019. The presentation will be webcast live at http://wsw.com/webcast/evercore4/anip/. The live webcast will be archived and available through the prior link for 90 days following the presentation.
- Thomson Reuters StreetEvents
Edited Transcript of ANIP earnings conference call or presentation 6-Nov-19 3:30pm GMT
Q3 2019 ANI Pharmaceuticals Inc Earnings Call
- Simply Wall St.
Estimating The Intrinsic Value Of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of ANI Pharmaceuticals...
- Zacks
ANI Pharmaceuticals (ANIP) Lags Q3 Earnings and Revenue Estimates
ANI (ANIP) delivered earnings and revenue surprises of -16.89% and -10.25%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
ANI Pharmaceuticals Reports Third Quarter Results
BAUDETTE, Minn. , Nov. 6, 2019 /PRNewswire/ -- For the third quarter 2019: Net revenues of $51.3 million , an increase of 1% versus prior year  GAAP net income of $3.9 million and diluted GAAP earnings ...
- Benzinga
The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 5.) Agile Therapeutics Inc (NASDAQ: AGRX ) (follow-on ...
- PR Newswire
ANI Announces Plans to Launch Bretylium Tosylate Injection, USP 500mg/10ml (50mg/ml) for Ventricular Arrhythmias
BAUDETTE, Minn., Oct. 31, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced that its partner Pharmaceutics International Inc. (Pii) has received FDA approval of a Prior Approval Supplement for Bretylium Tosylate Injection, USP 500mg/10ml (50mg/ml). ANI plans to launch this currently unavailable drug in December, introducing this critical drug for the treatment of ventricular fibrillation and life-threatening ventricular arrhythmias, such as ventricular tachycardia.
- PR Newswire
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2019 Financial Results
BAUDETTE, Minn. , Oct. 30, 2019 /PRNewswire/ --Â ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2019 financial results on Wednesday, ...
- Zacks
ANI Pharmaceuticals (ANIP) to Report Q3 Results: Wall Street Expects Earnings Growth
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
